CIK 0001874252 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in P7 · fiscal year ends 12/31
| FY2025 | |
|---|---|
| Revenue (USD) | 537080 |
| Net income (USD) | -16.2 M |
| Diluted EPS (USD/shares) | -2.7 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-16 | 8-K | CURRENT REPORT items 5.02 | 2026-10-12 |
| 2026-10-09 | 8-K | CURRENT REPORT items 1.01,9.01 | 2026-10-09 |
| 2026-10-09 | 424B5 | PROSPECTUS SUPPLEMENT | |
| 2026-09-25 | 8-K/A | AMENDMENT NO. 1 TO FORM 8-K items 9.01 | 2026-07-15 |
| 2026-09-25 | 8-K | CURRENT REPORT items 7.01,9.01 | 2026-09-25 |
| 2026-08-14 | 10-Q | QUARTERLY REPORT | 2026-06-30 |
| 2026-08-12 | 4 | 4 | 2026-08-11 |
| 2026-08-10 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-07 | 4 | FORM 4 | 2026-08-05 |
| 2026-08-07 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-08-06 | 4/A | 4/A | 2026-07-22 |
| 2026-08-06 | 4/A | 4/A | 2026-07-22 |
| 2026-08-06 | 4/A | 4/A | 2026-07-22 |
| 2026-08-06 | 4/A | 4/A | 2026-07-22 |
| 2026-08-06 | 4/A | 4/A | 2026-07-22 |
| 2026-08-05 | 4 | 4 | 2026-07-31 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-07-24 | 8-K | CURRENT REPORT items 7.01,9.01 | 2026-07-24 |
| 2026-07-16 | 8-K | CURRENT REPORT items 2.01,7.01,8.01,9.01 | 2026-07-15 |
| 2026-07-09 | 3 | 3 | 2026-07-01 |
| 2026-07-07 | 4 | 4 | 2026-07-06 |
| 2026-07-07 | 8-K | CURRENT REPORT items 5.02,9.01 | 2026-07-01 |
Forms on file (last 1,000): 6-K 43, 8-K 22, 4 17, CORRESP 14, 3 11, 424B5 8, EFFECT 8, UPLOAD 8. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=QUCY (0.002 USD), /gw/filings/filings?ticker=QUCY&form=8-K, /gw/filings/facts?ticker=QUCY&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange